Scarica l'app Stockscreener
8.01
1.35%
-0.11
Dopo l'orario di chiusura:
8.00
-0.010
-0.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AUPH Giù?
Forum
Previsione
Frazionamento azionario
Aurinia Pharmaceuticals Inc Borsa (AUPH) Ultime notizie
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis - Business Wire
Layoff Tracker: Gilead Sciences Will Lay Off 104 Employees at California HQ - BioSpace
(AUPH) Technical Pivots with Risk Controls - Stock Traders Daily
GSA Capital Partners LLP Sells 102,373 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024 - sharewise
ARMISTICE CAPITAL, LLC's Strategic Reduction in Aurinia Pharmace - GuruFocus.com
Aurinia to Participate in Jefferies London Healthcare Conference - sharewise
Aurinia Pharmaceuticals Engages at London Conference - TipRanks
Aurinia Pharmaceuticals director Karen Smith sells $44,181 in stock - Investing.com India
Aurinia Pharmaceuticals director Karen Smith sells $44,181 in stock By Investing.com - Investing.com Australia
Aurinia Pharmaceuticals director sells shares valued at $38,415 - Investing.com India
Aurinia Pharmaceuticals director sells shares valued at $38,415 By Investing.com - Investing.com Canada
Aurinia Pharmaceuticals (NASDAQ:AUPH) Upgraded at StockNews.com - Defense World
Aurinia Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations - Simply Wall St
Aurinia offers slimmer profile after investor pressure - The Pharma Letter
Leerink Partnrs Issues Optimistic Estimate for AUPH Earnings - MarketBeat
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2024 Earnings Call Transcript - Insider Monkey
Aurinia Pharmaceuticals: A Potential Buyout Looms On The Horizon (NASDAQ:AUPH) - Seeking Alpha
Aurinia slashes workforce by 45% to focus on lupus and autoimmune assets - Pharmaceutical Technology
Aurinia stock jumps 14% on Q3 earnings, restructuring announcement - MSN
Earnings call: Aurinia Pharmaceuticals announced a 24% increase in total net revenue - Investing.com
Aurinia Pharmaceuticals Inc (AUPH) Quarterly 10-Q Report - Quartz
Aurinia Pharmaceuticals Announces Restructuring - citybiz
Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Price Up 11%Should You Buy? - MarketBeat
Aurinia: Q3 Earnings Snapshot - The Washington Post
Aurinia stock jumps 14% on Q3 earnings, restructuring announcement (NASDAQ:AUPH) - Seeking Alpha
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development - sharewise
Aurinia Pharmaceuticals (AUPH) Q3 Earnings and Revenues Beat Estimates - Yahoo Finance
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors - citybiz
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth - Business Wire
Long Term Trading Analysis for (AUPH) - Stock Traders Daily
Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) are in the red if they invested three years ago - Yahoo Finance
Aurinia Pharmaceuticals (AUPH) to Release Earnings on Thursday - MarketBeat
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024 - The Bakersfield Californian
Axonis Therapeutics Announces $115 Million Series A Financing - Quantisnow
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) surges 5.9%; individual investors who own 51% shares profited along with institutions - Simply Wall St
Objective long/short (AUPH) Report - Stock Traders Daily
Oppenheimer Downgrades Aurinia Pharmaceuticals Inc (AUPH) to a Perform from an Outperform - Knox Daily
Adversity is less terrifying than hope: Aurinia Pharmaceuticals Inc (AUPH) - SETE News
AQR Capital Management LLC Takes Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - Defense World
AQR Capital Management LLC Buys Shares of 202,241 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) - MarketBeat
Aurinia Pharmaceuticals spotlights lupus nephritis drug - Investing.com India
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024 - BioSpace
Charting the Course: Aurinia Pharmaceuticals Inc’s AUPH Stock Prospects - The InvestChronicle
Aurinia Pharmaceuticals Showcases LUPKYNIS’s Impact at ASN 2024 - TipRanks
Aurinia Pharmaceuticals spotlights lupus nephritis drug By Investing.com - Investing.com UK
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):